A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Topics Massachusetts
Was this article valuable?
Here are more articles you may enjoy.
Update: Catastrophe Bond Investors Told to Brace for Jamaica Payout 
Old Republic to Acquire Small Farmowner Insurer Everett Cash Mutual 
Chubb Books Record P/C Underwriting Income, Combined Ratio in Q3 
World’s Largest Retirement Community Taps Muni Market to Help Build More Homes 
